Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Adults

Phase 3, randomised, double-blind trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated) in influenza (4 arms), sponsored by Sanofi. Primary endpoints: Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines With Corresponding B Strain at Day 21, Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or After Trivalent Influenza Vaccines Without Corresponding B Strain at Day 21 and 1 more. Started Oct 2010; status: completed.